from Keith S on yahoo mb...
"Tepotinib efficacy in an NSCLC patient with brain metastasis harboring an HLA-DRB1-MET gene fusion" (interesting mutations)
"Cabozantinib was well tolerated, with the main adverse event being grade 1 xerostomia. At last follow-up
in November 2019, the patient was asymptomatic, in good physical condition (ECOG PS of 1), and still on cabozantinib. The timeline of the patient’s disease course and interventions are illustrated in Figure 4.
To our knowledge, this is the first report of a patient with NSCLC harboring an HLA-DRB1-MET gene fusion demonstrating a clinical response to multiple MET inhibitors, including tepotinib. This finding illustrates the efficacy and rationale to targeting MET regardless of fusion partner and gives insight to pooling of patients with different MET fusion products in trials assessing safety and efficacy of novel molecules."